The first FDA-approved device to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
FDA cleared the first-and-only calcitonin gene-related peptide (CGRP) antibody for cluster headaches.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.
FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).
Express Scripts, a Cigna company, plans to launch the industry's first stand-alone digital health formulary.
FDA approved some important new therapies, including the first anticoagulant for children, an injectable for diabetic retinopathy, and a treatment for renal cell carcinoma.
Generic drug makers are defending their practices after 44 US states accused Teva Pharmaceuticals and other pharma makers of conspiring to inflate their prices in a lawsuit.
A new government rule requiring pharma makers to disclose drug prices in television ads will likely create more confusion for consumers, analysts and organizations said.